AMD, Absci

AMD Invests in Drug-Discovery Company Absci in Push to Sell AI Chips
The $20 million deal gives the chip supplier a toehold in the life-sciences market, a strategy it plans to replicate in other industries.
Absci Stock Jumps As AMD Invests $20M To Boost AI Drug Discovery
AI drug creation company Absci Corporation (NASDAQ:ABSI) shares are trading higher in premarket on Wednesday after the company entered into a strategic collaboration with Advanced Micro Devices Inc (NASDAQ:AMD) to enhance its AI drug discovery capabilities.
AMD invests $20M in AI-powered drug discovery company Absci
Absci will use AMD’s $20 million investment to enhance its AI models. In parallel, the companies will collaborate to develop new hardware and software optimized for the healthcare sector. The effort will place particular emphasis on developing technologies that can advance drug discovery.
AMD invests $20 million in AI drug research at Vancouver-based Absci
Chip designer AMD said Wednesday that it will invest $20 million in Absci, the Vancouver company that aims to use artificial intelligence to develop new drug therapies. Absci hopes artificial intelligence will enable it to move faster to develop protein-based medicines called biologics,
Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery
Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct™ accelerators and ROCm™ software to power critical AI drug discovery workloads,
Absci stock soars on AMD partnership and investment
Investing.com -- Shares of Absci Corporation (NASDAQ: ABSI) soared 50% following the announcement of a strategic collaboration and a $20 million investment from AMD (NASDAQ: AMD ). The partnership aims to enhance Absci's AI-driven drug discovery capabilities using AMD's Instinct accelerators and ROCm software.
AbSci’s Strategic Growth Bolstered by AMD Collaboration and Promising Pipeline Advancements
Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on AbSci (ABSI – Research Report) and keeping the price target at ...
AMD is going head-to-head with Nvidia in AI-backed drug discovery with new deal
Chip maker AMD is investing $20 million in AI drug startup Absci, which will use AMD chips and software for drug development.
AMD Shares Slide as HSBC Downgrades Stock Over Nvidia Concerns; Absci Collaboration Announced
Following HSBC downgrading of the semiconductor company's stock, Advanced Micro Devices ( AMD, Financials) shares fell over 5 ...
AMD首次布局生命科学！投资AI药企以扩大其AI芯片份额
AMD 和英伟达的角力，有时是彼此推出同类竞品，有时是通过布局新的领域。当地时间 1 月 8 日，AMD 首次进军生命科学领域，其以私募股权投资形式（PIPE 交易）向 AI 药物研发公司 Absci 投资 2000 万美元，有望帮助 AMD 增加其 ...
AMD战略携手Absci，2000万美元加码AI新药研发
近日，专注于生成式人工智能新药研发的Absci Corporation宣布了一项与AMD的战略合作计划，旨在通过部署AMD Instinct加速器和ROCm软件，为Absci的关键新药研发工作负载提供强大支持，特别是其创新的从头抗体设计模型。
AMD投资2000万美元于Absci以扩大人工智能芯片在医疗保健板块的销售 - 华尔街日报
Investing.com -- 据华尔街日报报道，美国超微公司AMD计划向华盛顿州的药物发现公司Absci投资2000万美元，旨在增加其人工智能 (AI)芯片在医疗保健板块的使用。